Clinical biomarkers forum: Harnessing the potential of biomarkers from translational research throughout clinical trials

Expert Review of Molecular Diagnostics

Volumn 7, Issue 6, 2007, Pages 759-760

  Shaw, Martin ^a  

^a Biotrin International   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CISPLATIN; GLUTATHIONE TRANSFERASE ALPHA; INHIBIN; LIPOCALIN; TRASTUZUMAB; TROPONIN;

CANCER PATIENT; CELL CULTURE; CLINICAL RESEARCH; CLINICAL TRIAL; CONFERENCE PAPER; DRUG COST; DRUG INDUSTRY; DRUG SCREENING; DRUG SYNTHESIS; FLOW CYTOMETRY; GENE EXPRESSION; HEALTH PROGRAM; HUMAN; MEDICAL DECISION MAKING; NONHUMAN; PRODUCTIVITY;

ANIMALS; BIOLOGICAL MARKERS; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; DRUG INDUSTRY; HUMANS; RESEARCH;

EID: 36448968648     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/14737159.7.6.759     Document Type: Conference Paper

References (3)

1. Crawford LM. Acting commissioner of the FDA's speech to the drug information association (2004) www.fda.gov/oc/speeches/2004/dia1026.html
2. The Critical Path Institute www.c-path.org
3. ILSI: Development and Application of Biomarkers of Toxicity www.hesiglobal.org/Committees/Technical Committees/Biomarkers